NCT02659033View on ClinicalTrials.gov

Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal.

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

March 31, 2016

Study Completion Date

December 31, 2017

Conditions

Emergence of Bacterial Resistance to Antibiotics

Interventions

DRUG

ceftriaxone

ceftriaxone (1 gram per day)

DRUG

Cefotaxime

cefotaxime (1 gram every 8 hours)

Trial Locations (1)

75018

Hôpital Bichat, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02659033 - Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal. | Biotech Hunter | Biotech Hunter